Effect of the composition of combined solid lipid particles with gefitinib and a photosensitizer on their size, stability and cytotoxic activity-Reference-Cited by-同舟云学术

Effect of the composition of combined solid lipid particles with gefitinib and a photosensitizer on their size, stability and cytotoxic activity

Published:2024-07-31 Issue:2 Volume:13 Page:19-25
ISSN:2413-9432
Container-title:Biomedical Photonics
language:
Short-container-title:Biomedical photonics

Author:

Nikolaeva L. L.¹,Sanarova E. V.²,Kolpaksidi A. P.²,Shcheglov S. D.¹,Rudakova A. A.²,Baryshnikova M. A.²,Lantsova A. V.²

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Abstract

The creation of combined nanomedicines and their controlled release under the influence of photoinduction is an actively developing branch of scientific research. This work is devoted to the development of models of solid lipid nanoparticles for a well-known antitumor drug – gefitinib in combination with a photoindicating agent – a photosensitizer from the phthalocyanine group. Nanoparticles were obtained by several methods: hot homogenization with stearic acid, sesame oil and Tween 80 and by one-step dispersion with copolymers of lactic and glycolic acids and polyvinyl alcohol. In vitro experiments when irradiating particles with a laser in the near-infrared range (about 730 nm) proved the advantage of using combined nanoparticles with gefitinib and a photosensitizer compared to monotherapy, while the activity in terms of IC50 was 5.1-8.7 times higher for gefitinib and 1.5-1.8 times for the photosensitizer.

Publisher

Russian Photodynamic Association

Reference13 articles.

1. Jampilek J., Kralova K. Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy. Pharmaceutics, 2022, vol. 14(12), pp. e2706. doi: 10.3390/pharmaceutics14122706.

2. Nadaf S.J., Killedar S.G., Kumbar V.M., Bhagwat D.A., Gurav S.S. Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic eŠcacy against non-small cell lung cancer. International Journal of Pharmaceutics, 2022, vol. 628, pp.. e122287. doi: 10.1016/j.ijpharm.2022.122287.

3. Kumar V., Khan I., Gupta U. Lipid-dendrimer nanohybrid system or dendrosomes: evidences of enhanced encapsulation, solubilization, cellular uptake and cytotoxicity of bortezomib. ApplNanosci, 2020, vol. 10, pp.. 4049-4062. doi: 10.1007/s13204-020-01515-7.

4. Gracias S., Ayyanar M., Peramaiyan G., Kalaskar M., Redasani V., Gurav N., Nadaf S., Deshpande M., Bhole R., Khan M.S., Chikhale R., Gurav S. Fabrication of chitosan nanocomposites loaded with biosynthetic metallic nanoparticles and their therapeutic investigation. Environmental Research, 2023, vol. 234, pp.. e116609. doi: 10.1016/j.envres.2023.116609.

5. Meerovich I., Nichols M.G., Dash A.K. Low-intensity light-induced paclitaxel release from lipid-based nano-delivery systems. Journal of Drug Targeting, 2019, vol. 27(9), pp.. 971-983. doi: 10.1080/1061186X.2019.1571066.